Endotracheal intubation with direct laryngoscopy can cause undesirable haemodynamic effects such as hypertension and tachycardia 1 . Moreover, endotracheal intubation during rapid sequence induction can evoke more profound haemodynamic responses due to the use of succinycholine and rapid induction 2,3 . In the past, thiopentone has been induction agent of choice for rapid sequence induction. However, propofol has been used more commonly 4,5 . Although its use for rapid sequence induction can cause thiopentone 6 .
MATERIALS AND METHODS
After obtaining approval from our local hospital ethics committee and informed consent, 48 ASA physical status 1-2 male patients presenting for elective surgery were enrolled in this study. The investigators were also blinded to the identity of the study drug. Accordingly, patients were randomly assigned according to the computer generated random number sequence into one of three groups, each of 16 patients, to receive the following study drugs in a double-blind manner: normal saline 0.1 ml/kg (Group NS), remifentnail 1 μg/kg (Group R), lignocaine 1.5 mg/kg (Group L). Study drugs were prepared by a nurse who was not involved in anaesthesia provision (normal saline 10 ml, remifentanil 100 μg in 10 ml, lignocaine 150 mg in 10 ml).
polyvinyl catheter was placed in the radial artery to monitor arterial blood pressure continuously. Glycopyrrolate 0.2 mg was administered IV. After three minutes preoxygenation, anaesthesia was inloss of consciousness, the study drug 0.1 ml/kg was injected over 30 seconds while maintaining cricoid pressure, followed by succinycholine 1 mg/kg. After 60 seconds, the trachea was intubated with a 7.5 mm ID endotracheal tube under direct laryngoscopy. All of the intubations were performed by the same investigator. The patient's lungs were ventilated with intubaton. Further movement was prevented with 6 mg of vecuronium bromide IV.
Mean arterial pressure (MAP) and heart rate (HR) were recorded at baseline, at loss of consciousness, just before laryngoscopy and every minute for 10 minutes after intubation.
The calculation of required sample size was based on mean and SD of change in MAP after intubation in previous investigations and our pilot study 12, 14 . This group to detect a 20 mmHg difference in change in MAP, accepting an alpha error of 5% and a beta error of 20%. The groups were compared using repeated measured analysis of variance and one-way analysis of variance with Tukey test. A P value of within group differences between the baseline and the value at each time were compared using paired t-test with adjusted P value 0.0042. A P value of less than RESULTS characteristics between the groups ( Table 1) .
The sequential changes of MAP in three groups are shown in Figure 1 . The changes of MAP with time between three groups were different (P<0.001 in repeated measured ANOVA). After injection of propofol 2 mg/kg, MAP decreased by approximately 18% of baseline values in all groups (P<0.001). One minute after intubation, MAP in Group NS and Group L increased by 46% and 38% of baseline values respectively (P<0.001), while MAP in Group R returned to baseline value. MAP in Group NS and Group L returned to the baseline four minutes after intubation. Although MAP in Group R remained below the baseline after three minutes, there was no
The sequential changes of HR in three groups are shown in Figure 2 . The changes of MAP with time between three groups were different (P=0.009 in repeated measured ANOVA). HR did not change in all groups after injection of propofol. One minute after intubation, HR in Group NS and Group L increased by 27% and 31% of baseline values respectively (P< 0.001). HR in Group R decreased by 18% of baseline value after the administration of remifentanil and succinycholine (P=0.002), but returned to baseline value one minute after intubation. Although HR in Group R remained below the baseline after six
DISCUSSION
Our study demonstrates that remifentanil 1 μg/kg, but not lignocaine 1.5 mg/kg, attenuates the pressor response to intubation when propofol, glycopyrrolate and succinycholine are used for rapid sequence induction.
Both laryngoscopy and intubation cause a haemodynamic response independently of each other and the mechanism of blunting the response may be different for each. The current study assessed only the response to combined laryngoscopy and intubation. The laryngoscopy and intubation during rapid sequence induction have been frequently associated with hypertension and tachycardia 2 . To attenuate the pressor response to brief but noxious stimuli of rapid tracheal intubation, the supplement to the induction drug should be potent but have a short duration of action. Additionally, considering the fast process of rapid sequence induction, the rapid onset of drug effect is mandatory. Remifentanil can rapidly provide intense analgesia with short duration 13, 14 . In this respect, remifentanil can be superior to other opioids such as fentanyl. Hypotension is more frequently encountered when propofol is used as an induction agent compared to thiopentone 6 . Remifentanil 1.25 μg/kg has been of patients 16 . However, our study suggests that remifentanil 1 μg/kg can successfully attenuate the haemodynamic response to endotracheal intubation without the induction agent during rapid sequence induction. on the haemodynamic response to endotracheal intubation during rapid sequence induction using 11 . The timing of lignocaine injection could be important for blunting the haemodynamic response to endotracheal intubation. Tam et al showed lignocaine minutes before laryngoscopy 8 . Although the relatively late administration of lignocaine (one or two minutes before intubation) may be the reason for the ineffectiveness of lignocaine in this study, the need for careful timing suggests that the usefulness of lignocaine to blunt the haemodynamic response during rapid sequence induction using propofol is questionable.
In our study, glycopyrrolate 0.2 mg was used to prevent excessive secretions and bradycardia. Because the administration of remifentanil and succinycholine following the injection of propofol often decreases HR, a vagolytic agent should be considered for the prevention of severe bradycardia. A previous study has shown that glycopyrrolate 0.2 mg given immediately before remifentanil does not produce tachycardia but attenuates bradycardia 15 . Therefore, we used glycopyrrolate in the current study.
This study was conducted in young male patients without cardiovascular disease. Our results may not apply to patients with advanced cardiovascular disease, who might have a more exaggerated response to both induction and intubation. Therefore, the studies in more at risk patients are required.
In conclusion, in ASA PS 1-2 patients, remifentanil 1 μg/kg effectively blunts the haemodynamic response to intubation during rapid sequence induction using glycopyrrolate, propofol and succinylcholine, whereas lignocaine 1.5 mg appeared to be ineffective.
